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Klinikum Berlin Buch, Berlin, GermanyAntiphospholipid antibodies induce a prothrombotic state potentially causing arterial and venous thromboembolism.
Anticardiolipin antibodies, b2-glycoprotein-1-antibodies and lupus anticoagulant have been identified most commonly.
We describe a rare case of venous and recurrent arterial thromboembolic events in a 67-year-old female with high
concentrations of antiprothrombin antibodies without clinical or serological evidence of connective tissue disease.
To avoid misdiagnosis and treatment and to improve the likelihood of recognizing antiphospholipid-syndrome we therefore
strongly recommend testing for prothrombin antibodies in case of negative or inconclusive standard tests for
antiphospholipid syndrome..
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Antiphospholipid antibodies are known to induce a
prothrombotic state causing arterial and venous
thromboembolism.1 Anticardiolipin antibodies are
most often found in affected patients with or without
connective tissue disease, but b2-glycoprotein-1-anti-
bodies and lupus anticoagulant have also been
identified. There is a growing body of evidence
about the interrelations of these antibodies and their
mechanisms causing endothelium activation and
hypercoagulation.1–5
Several reports have described antibodies with
prothrombin binding activity in patients with throm-
bosis and antiphospholipid-antibody syndrome
associated with connective tissue disorders.2,4,6–13ing author. Peter Klein-Weigel, MD, Klinik fu¨r physi-
rehabilitative Medizin, Schwerpunkt Angiologie, DRK
lin-Ko¨penick, Salvador-Allende Str. 2-8, 12559 Berlin,
: p.klein-weigel@drk-kliniken-koepenick.de
2005 Elsevier Ltd. Open access under CC BY-NC-ND license.We describe a rare case of venous and recurrent
arterial thromboembolic events in a 67-year-old
female with high concentrations of antiprothrombin
antibodies without clinical or serological evidence of
connective tissue disease.Case Report
A 67-year-old Caucasian female was admitted to
our institution with subacute lower limb ischemia.
Clinically, there was no family clustering of throm-
boembolism, and no history of thrombocytopenia,
fetal loss, stroke or myocardial infarction.
Duplex sonography and DSA identified thrombotic
material in both iliac arteries, occlusion of both distal
femoro-popliteal arteries, and a right popliteal vein
thrombosis. Pulmonary emboli and embolic sources in
the aorta were excluded by CT-A. The presence of a
cardiac thrombus and a possible patent foramen ovale
were excluded by transesophageal echocardiography
(TEE) (Fig. 1 and 2).EJVES Extra 11, 26–28 (2006)
doi:10.1016/j.ejvsextra.2005.11.002, available online at http://www.sciencedirect.com on
Fig. 1. DSA at fist admission showing thrombotic material in
both iliac arteries and thromboembolic occlusion of the distal
femoral and popliteal arteries.
Fig. 2. DSA at re-admission showing left femoral artery
occlusion.
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was performed immediately after admission.
Perioperatively, the patient was treated with
intravenous unfractionated heparin. Unfortunately,
the patient refused further heparin injections as well
as warfarin and, therefore, was discharged on 100 mg
aspirin and 75 mg clopidogrel.
A few days later the patient had to be re-admitted
with critical left limb ischemia due to thromboembolic
re-occlusion of the femoral and crural arteries in her
left leg. She was successfully treated by Fogarty
catheter thrombo-embolectomy and patch angioplasty
of the common femoral artery. Postoperatively, she
received unfractionated heparin (aPTT 50–70 s) intra-
venously and, after giving informed consent, oral
anticoagulation therapy was started with a targetinternational normalised ration (INR) in the range of
2.5–3.5.
Screening for thrombophilia including HIT II, APC-
RI, Prot. C, Prot. S, AT, G20210A and Factor V-Leiden
was negative apart from a mild hyperhomocysteine-
mia (16.1 mmol/l (!12 mmol/l)). Furthermore, dRVVT
(32.0 s (31–44 s)) and LA-sensitive aPTT tests (24.3 s
(26–34 s)) were within normal limits, excluding
presence of LA. ANA (!1:80), aCL IgG (12.8 kU/l
(!48 kU/l)), aCL IgM (41.4 (!44 kU/l)), as well as b2-
GP-1 antibodies (3.9 (!5.1 kU/l)) all revealed normal
levels. However, we found markedly elevated anti-
prothrombin antibodies: O100 kU/l (!30 kU/l).Discussion
We report recurrent arterial and venous thromboem-
bolism in a patient with high levels of prothrombin
antibodies without evidence of connective tissue
disease. This may indicate the presence of a primary
antiphospholipid syndrome induced by prothrombin
antibodies. Remarkably, aCL antibodies and b2-GP-1
antibodies were not elevated and LA-sensitive coagu-
lation tests were not prolonged.
Prothrombin antibodies occur in about 30–50% of
patients with SLE and about 20% of patients with
systemic sclerosis and have been associated with
thromboembolic complications in these patients.4,6,9,12
Their presence in thromboembolism not associated
with connective tissue diseases is rare.10–12
Antiphospholipid antibodies recognise plasma pro-
teins bound to anionic surfaces.2 Besides b2-GP-1,
prothrombin seems to be the second major bindingEJVES Extra Vol 11, February 2006
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ing, bivalent stable complexes are formed on coagu-
lation active phospholipids.5 These complexes were
found to activate endothelium cells.5 and to inhibit the
APC-catalysed F Va inactivation.8
Antibodies against prothrombin are not hom-
ogenous. A recent study reported that 12.5% were
specific for pure prothrombin, 31.9% for phosphati-
dylserine/prothrombin-complexes and 55.6% recog-
nised both antigenic forms.11
The preferred location of prothrombin-antibody
induced thrombosis, venous or arterial, is still
unclear.10,12,13 More accurate diagnostic techniques
will be required in order to link particular autoanti-
bodies with different clinical presentations.2
Almost 50% of patients with SLE and clinical
features of aPL syndrome who are negative for
standard tests have prothrombin antibodies.6
Although antiprothrombin antibodies are in general
not very helpful to define the patient’s risk, due to
standardisation problems,7 testing is likely of clinical
benefit in patients who are negative for standard tests.6
Opinions concerning treatment of antiphospholipid
syndrome vary widely.1 Combined treatment with
antiplatelet agents, i.e. ASS and clopidogrel, did not
prevent arterial re-thrombosis in our patient. In
contrast, oral anticoagulant therapy with an INR
range of 3.0–3.5 prevented re-occurrences, but the
optimal duration of this therapy remains unknown.
It seems not very likely that mild hyperhomocys-
teinemia as additionally detected in our patient was
responsible for the severe thromboembolic compli-
cations. On the other hand it cannot be excluded that
hyperhomocysteinemia might have added to the
prothrombotic state.
To avoid misdiagnosis and to improve the likelihood
of recognising antiphospholipid-syndrome we would
strongly recommend testing for prothrombin anti-
bodies in cases of recurrent thromboembolic compli-
cations where negative or inconclusive standard tests
for antiphospholipid syndrome have been obtained.EJVES Extra Vol 11, February 2006References
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